Fate Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 07:05PM GMT
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone and welcome to Barclays Global Healthcare Conference. We're in Miami, and do raise your hand or e-mail us if you have questions. My name is Peter Lawson. I'm one of the mid-cap biotech analyst at Barclays, focusing on oncology, really delighted to have up on stage with me, the CEO from Fate, Scott Wolchko.

Questions and Answers:

Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst

And I guess the first question is really kind of I guess, opponent from most people is just kind of J&J collaboration kind of how that unfolded if you can kind of shed any more light around...

J. Scott Wolchko - Fate Therapeutics, Inc. - Founder, CEO, President & Director

Sure -- I mean I'll do as best as I can with it. It certainly is a bit of a surprise. We were making a lot of progress under the J&J collaboration. Headed into the fourth quarter, J&J had already exercised a commercial
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot